Clinical OMICS

MAR-APR 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 49 of 51 March/April 2019 Clinical OMICs 48 Microbiome Movement — Maternal & Infant Health May 22–24, Boston The 1st Microbiome Movement – Maternal & Infant Health Summit brings together large pharma, biotech companies, research institutes, and technology experts to harness the causality of maternal-infant microbiome and translate it into therapeutic, nutritional, and preventative solutions for early life health outcomes. Key topics include discovering causal relationships between the maternal-infant microbi- ome and disease onset and exploring different therapeu- tic products that restore the infant microbiome, as well as treat and prevent disease. Attendess can expect to learn about study design for investigation of the microbiome in maternal and pediatric settings; the role of the maternal microbiome in preterm birth and infant health outcomes; how to integrate omics data with novel preclinical model- ling to generate clinically meaningful results; regulatory processes for IND-approved products targeting maternal and infant populations; and public health, economic, and educational considerations for commercializing microbi- ome-based products for mothers and infants. This new con- ference promises to unlock the full potential of preventative, therapeutic and nutritional solutions in the key window of opportunity of the first 1000 days of life. ASCO Annual Meeting May 31–June 4, Chicago ASCO offers a robust program designed to teach, engage, and bring the oncology field together. In addition to pre- senting the latest research in cancer care, the program will feature world-renowned faculty discussing state-of- the-art treatment modalities, new therapies, and ongo- ing controversies in the field. Learn more about the program offerings this year, including featured sessions and pre-Annual Meeting Seminars. The Annual Meeting brings together more than 30,000 oncology profession- als from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. The conference program includes a wide variety of sessions: educational ses- sions, plenary session, meet the professor, clinical science symposia, and poster presentations session. Pre-meeting seminars will be from 1:00 p.m. to 5:00 p.m. on May 30, and 7:30 a.m. to 11:00 a.m. on May 31. When not attending cutting-edge pre- sentations, attendees can visit the exhibit hall with more than 440 exhibiting companies. Biomarker World Congress June 17–19, Ann Arbor, MI Cambridge Healthtec Institute's Biomarker World Con- gress is now a part of World Pharma Week. Now in its 15th year, Congress is the longest-running event dedicated to all areas of biomarker research and development spanning the pharmaceutical and diagnostic pipelines. With the promising developments in immuno-oncology, significant biomarker R&D has shifted to discovery and development of predictive biomarkers for immunotherapy patient strat- ification, using biomarker or mechanism data to choose rational combination immunotherapy, and applying immune profiling to predict response to immunotherapy. Advances in clinical and translational biomarkers will also be covered, including patient selection and predicting response to therapy, liquid biopsy and cell free DNA, com- panion diagnostics and personalized medicine, biomarker assay development and validation, and biomarker-based clinical trials. Next Generation Dx Summit August 20–22, Washington, DC Next Generation Dx Summit attracts more than 800 inter- national diagnostic professionals for the latest develops in the industry ranging from biomarker identification and clinical diagnostic development to precision medicine and business strategy. Celebrating its 11th year, the conference spans point-of-care testing, infectious disease diagnostics, companion diagnostics, liquid biopsy, digital pathology and AI, immuno-oncology, insurance coverage and reimburse- ment, and commercialization of diagnostics. Short course topics during the conference include technolo- gies, applications and commercialization of POC Dx, tumor mutation burden, and data-driven process develop- ment in the clinical laboratory, among others. Brand X Pictures / Digital Vision Vectors / Getty Images Industry Events

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2019